Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹18,027 Cr
Revenue (TTM)
₹1,575 Cr
Net Profit (TTM)
₹179 Cr
ROE
18.5 %
ROCE
23.5 %
P/E Ratio
100.6
P/B Ratio
10.9
Industry P/E
34.1
EV/EBITDA
52.8
Div. Yield
0.1 %
Debt to Equity
0.1
Book Value
₹1293.7
EPS
₹139.6
Face value
10
Shares outstanding
12,829,889
CFO
₹1,287.55 Cr
EBITDA
₹1,744.60 Cr
Net Profit
₹986.82 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| -7.4 | 7.8 | -7.1 | 28.2 | 89.7 | 41.9 | 34.5 |
|
BSE Healthcare
| -3.1 | -3.4 | -6.0 | 7.2 | 23.7 | 13.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| 6.2 | 159.8 | 217.4 | 7.9 | 41.7 | 161.5 | -12.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neuland Lab
|
14,055.0 | 18,026.8 | 1,575.1 | 179.1 | 14.9 | 11.4 | 100.6 | 10.9 |
| 361.6 | 3,297.1 | 2,521.8 | 202.5 | 9.6 | 14.3 | 16.3 | 2.2 | |
| 1,044.3 | 12,804.5 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.6 | 4.0 | |
| 374.5 | 6,495.4 | 1,053.1 | 293.6 | 32.3 | 24.6 | 22.1 | 5.0 | |
| 1,049.8 | 10,983.7 | 1,158.7 | 309.6 | 31.9 | 17.3 | 35.1 | 5.8 | |
| 1,565.4 | 29,661.3 | 8,850.1 | 894.8 | 15.2 | 19.8 | 34.1 | 6.0 | |
| 282.1 | 3,081.0 | 159.3 | 47.8 | 39.0 | 18.6 | 64.5 | 11.1 | |
| 1,872.6 | 3,114.7 | 673.7 | 202.6 | 17.6 | 19.4 | 15.4 | 5.4 | |
| 783.3 | 3,608.1 | 588.5 | 102.9 | 22.1 | 12.7 | 35.5 | 4.3 | |
| 169.1 | 4,458.2 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 6.7 |
1 min read•By Research Desk
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics,... cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Incorporated
1984
Chairman
Davuluri Rama Mohan Rao
Managing Director
Davuluri Saharsh Rao
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Neuland Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsAnnouncement under Regulation 30 (LODR)-Demise
03-Mar-2026
The share price of Neuland Laboratories Ltd is ₹14,055.00 (NSE) and ₹14,092.30 (BSE) as of 08-Apr-2026 IST. Neuland Laboratories Ltd has given a return of 89.69% in the last 3 years.
The P/E ratio of Neuland Laboratories Ltd is 100.63 times as on 08-Apr-2026, a 195 premium to its peers’ median range of 34.10 times.
The P/B ratio of Neuland Laboratories Ltd is 10.86 times as on 08-Apr-2026, a 396 premium to its peers’ median range of 2.19 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
59.57
|
10.17
|
|
2024
|
26.86
|
6.29
|
|
2023
|
14.12
|
2.32
|
|
2022
|
20.64
|
1.57
|
|
2021
|
33.22
|
3.41
|
The 52-week high and low of Neuland Laboratories Ltd are Rs 19,747.00 and Rs 10,578.00 as of 09-Apr-2026.
Neuland Laboratories Ltd has a market capitalisation of ₹ 18,027 Cr as on 08-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Neuland Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹879.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.